The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
- PMID: 30793003
- PMCID: PMC6377935
- DOI: 10.1093/ofid/ofz007
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
Abstract
Background: To estimate the health care resource utilization, costs, and impact on quality of life (QoL) of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥50 years in Italy.
Methods: This was a prospective, observational, multicenter, community physician-based surveillance study (NCT01772160) in Italy. Health-related QoL data were collected using the EuroQoL-5 Dimension (EQ-5D) and Zoster Brief Pain Inventory (ZBPI) questionnaires. Both questionnaires were assessed at days 0 (HZ rash onset), 15, 30, 60, and 90 for all patients, and monthly thereafter for patients who developed PHN. Resource utilization was recorded for 3 months post-HZ onset and 9 months for PHN patients. Costs from both payer and societal perspectives were estimated and were composed of direct medical costs (general practitioner/specialist visits, procedures, hospitalizations, medications), work loss by patient/caregiver, and transport costs.
Results: A total of 391 patients with HZ were included, of whom 40 developed PHN. The mean ZBPI worst pain score was 5.7 at day 0, reducing to 2.6 at day 30 and 0.7 by day 90. Patients with PHN had a mean worst pain score of 5.7 at day 90. We estimated an overall disutility associated with HZ of 0.134. The mean cost per HZ patient from a payer/societal perspective was €153/€298, respectively, and the mean cost per HZ patients who developed PHN was €176/€426, respectively.
Conclusions: HZ is associated with impaired QoL and substantial health care resource use, highlighting the need for preventive strategies. This could reduce the disease burden for the patient and health care system.
Clinicaltrialsgov study registry: NCT01772160.
Keywords: QALY; economic burden; herpes zoster (HZ); postherpetic neuralgia (PHN); quality of life (QoL).
Figures



Similar articles
-
Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above.BMC Infect Dis. 2018 Oct 3;18(1):496. doi: 10.1186/s12879-018-3395-z. BMC Infect Dis. 2018. PMID: 30285731 Free PMC article.
-
Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study.Adv Ther. 2021 Jun;38(6):3325-3341. doi: 10.1007/s12325-021-01717-7. Epub 2021 May 19. Adv Ther. 2021. PMID: 34013498 Free PMC article.
-
Impact of Herpes Zoster and Postherpetic Neuralgia on the Quality of Life in China: A Prospective Study.Clin Cosmet Investig Dermatol. 2024 Aug 26;17:1905-1915. doi: 10.2147/CCID.S471823. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39220293 Free PMC article.
-
The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.BMC Public Health. 2015 Feb 27;15:193. doi: 10.1186/s12889-015-1514-y. BMC Public Health. 2015. PMID: 25880058 Free PMC article. Review.
-
Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.Aging Clin Exp Res. 2009 Jun;21(3):236-43. doi: 10.1007/BF03324909. Aging Clin Exp Res. 2009. PMID: 19571648 Review.
Cited by
-
Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.Psoriasis (Auckl). 2024 Jun 22;14:63-78. doi: 10.2147/PTT.S430151. eCollection 2024. Psoriasis (Auckl). 2024. PMID: 38939905 Free PMC article.
-
A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation.Plants (Basel). 2022 May 20;11(10):1357. doi: 10.3390/plants11101357. Plants (Basel). 2022. PMID: 35631782 Free PMC article. Review.
-
Early Diagnosis of Herpes Zoster Neuralgia: A Narrative Review.Pain Ther. 2023 Aug;12(4):893-901. doi: 10.1007/s40122-023-00510-4. Epub 2023 May 2. Pain Ther. 2023. PMID: 37129752 Free PMC article. Review.
-
Antiviral treatment in outpatients with herps zoster in six major areas of China, 2010-2019.Front Public Health. 2022 Jul 29;10:942377. doi: 10.3389/fpubh.2022.942377. eCollection 2022. Front Public Health. 2022. PMID: 35968424 Free PMC article.
-
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):485-490. doi: 10.1093/gerona/glaa127. J Gerontol A Biol Sci Med Sci. 2021. PMID: 32530462 Free PMC article. Clinical Trial.
References
-
- Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3:335–42. - PubMed
-
- Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076–90. - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical